LENSAR, Inc. (LNSR) stock intrinsic value fair value estimate & owner earnings analysis

LENSAR makes femtosecond laser systems used in cataract surgery. Its current platform, the ALLY System, was cleared by the FDA in June 2022 and launched from August 2022. It is sold directly in the United States and through distributors in Europe and Asia. LENSAR earns most of its money after a laser is installed: every surgery needs a procedure license. In 2025 revenue was $58.4 million, and 79% of it was recurring (procedure licenses $33.8 million, up from $27.7 million, plus lease and service income). System sales were $12.1 million. The installed base grew from about 385 lasers at the end of 2024 to about 435 at the end of 2025. The competitors named in the filings are much larger: Alcon, Johnson & Johnson, Carl Zeiss, Bausch + Lomb and Ziemer. The central fact is that this business has never generated cash for its owners. We measure owner earnings as operating cash flow, with working-capital swings removed, less stock compensation and the capital needed to keep the business running. LENSAR builds some lasers and leases them to surgeons, and the filings show those units as inventory moved into leased equipment ($5.1 million in 2025, $9.1 million in 2024). We treat that as capital spending. On this basis owner earnings were negative in every year from 2019 to 2025: about -$11.4 million in 2023, -$10.5 million in 2024 and -$24.3 million in 2025. The 2025 figure includes $17.1 million of costs from the failed sale to Alcon. Without them, 2025 was about -$7.2 million. We start from the median of 2023 to 2025, the ALLY years, with 2025 adjusted for the deal costs. That starting point is about -$10.5 million a year. The Alcon deal matters. LENSAR agreed on March 23, 2025 to be acquired by Alcon. The FTC said it would seek to block the deal, and on March 16, 2026 the agreement was terminated. LENSAR kept Alcon's $10.0 million deposit. The filing says the pending deal disrupted the business and that some distributors reduced their activity. First-half 2026 revenue was $29.9 million, up only about 6.5% from a year earlier, and first-quarter revenue fell. The second quarter of 2026 produced an operating profit of about $2.1 million. First-quarter results were helped by a $4.3 million reversal of deal fees. Stripping that out, the first half was roughly break-even. One good quarter does not yet establish a new level. Share count matters too. There are about 12.3 million common shares. Convertible preferred stock (about 7.9 million shares if converted) and warrants bring the diluted count to about 24.0 million, and we value on that basis. The preferred can demand at least its roughly $20 million stated value in any change of control. Owner earnings are after interest, so we neither subtract debt nor add cash. Leverage is carried in the bear case. Base case ($1.30 per share): revenue grows 7% in 2026, matching the first-half pace. Growth then runs 10% in 2027 and 2028 as the installed base keeps adding procedure volume, 7% for three years and 5% after that. About 30 cents of each new revenue dollar reaches owner earnings, close to the 2023-2025 record. Owner earnings improve from about -$7.2 million in 2026, reach break-even around 2030, and reach about $7.8 million in 2035. We then carry that level for ten more years on the strength of the installed base, and nothing after. The early losses consume most of the value of the later profits. Bear case (-$2.56 per share): the damage from the failed deal and the pressure from larger rivals hold growth to 4% a year. Only 20 cents of each new dollar reaches owner earnings, and losses narrow slowly from about $10.5 million a year without ever turning positive within ten years. In this case the business uses up about $61 million more than it produces, in today's money. That is roughly $2.56 per share of value lost rather than created, paid for from cash on hand and new capital that would dilute shareholders. On these terms the company is worth less than nothing to its owners. Bull case ($14.19 per share): growth repeats the recent record, with 15% a year for three years (revenue grew 27% in 2024 and procedure revenue 22% in 2025), then 12% and 8%. About 40 cents of each new dollar reaches owner earnings. Owner earnings break even in 2027 and reach about $37 million by 2035 on revenue near $170 million, then hold for twenty more years. The very wide spread comes down to one question: can LENSAR fund itself? The margin-of-safety price is $1.90 per share, and it applies only after two more quarters of positive owner earnings, after leased-laser spending and stock compensation, beyond the second quarter of 2026. If that happens, the base case starts from break-even rather than from past losses. Its value then rises to about $4.74 per share, and $1.90 leaves a wide margin for a small, historically unprofitable company. Risks to watch are tariffs (the company flagged a changing tariff environment in 2026), South Korean reimbursement limits, and roughly $9.7 million of deal fees that were still unpaid at the end of 2025 after the $4.3 million reduction, $5.0 million of them on extended terms.